The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb’s best-selling products.
Shares in Bristol Myers Squibb Bristol Myers Squibb dipped Monday after the global biopharmaceutical company reached a deal to acquire Mirati Therapeutics, which specializes in cancer medicine, for up to $5.8 billion.
Mirati stock fell 1.7% to $59.20. The purchase price was less than Mirati’s closing price Friday of $60.20.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Consulte Mais informação »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Consulte Mais informação »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Consulte Mais informação »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Consulte Mais informação »
Exxon, Chevron, Mirati, Disney, Lockheed, and More Stock Market MoversExxon and Chevron shares rise after a surge in oil prices following the weekend attack on Israel from Hamas, Mirati Therapeutics stock falls after Bristol...
Consulte Mais informação »
1 Stock to Buy, 1 Stock to Sell This Week: JPMorgan Chase, CitigroupStocks Analysis by Investing.com (Jesse Cohen) covering: Citigroup Inc, JPMorgan Chase & Co, JP Morgan Chase & Co, Citigroup Inc. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Consulte Mais informação »